This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pauwels, B. Articles by Vermorken, J. B. Search for Related Content PubMed PubMed Citation Articles by Pauwels, B. Articles by Vermorken, J. B.

Combined Modality Therapy of Gemcitabine and Radiation

Laboratory of Cancer Research and Clinical Oncology, Department of Medical Oncology, University of Antwerp, Antwerp, Belgium

Correspondence: Bea Pauwels, Ph.D., Laboratory of Cancer Research and Clinical Oncology, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, 2610 Wilrijk, Belgium. Telephone: 32-38202576; Fax: 32-38202248; e-mail: bea.pauwels{at}ua.ac.be

The combination of gemcitabine and radiotherapy is a promising combined modality therapy. However, the clinical application of this combination has to be implemented carefully because of an increased toxicity to normal tissues. A body of experimental evidence shows that gemcitabine is a potent radiosensitizer in vitro and in vivo. The observations so far indicate that various mechanisms are responsible for the radiosensitizing effect. Although it is often difficult to transfer experimental data to the clinic, these studies offer the possibility to develop an improved schedule of administration for patient treatment, based on rational evidence in tumor biology. In the current review, the preclinical data that support the use of gemcitabine as a radiosensitizing agent and the clinical trials that have been conducted to date are summarized.

Key Words. Gemcitabine • Radiotherapy • Radiosensitization • In vitro • In vivo • Clinic

This article has been cited by other articles:

				R. J. Kimple, A. V. Vaseva, A. D. Cox, K. M. Baerman, B. F. Calvo, J. E. Tepper, J. M. Shields, and C. I. Sartor Radiosensitization of Epidermal Growth Factor Receptor/HER2-Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status Clin. Cancer Res., February 1, 2010; 16(3): 912 - 923. [Abstract] [Full Text] [PDF]

				H. G. Kang, Y. W. Roh, and H. S. Kim The treatment of metastasis to the femoral neck using percutaneous hollow perforated screws with cement augmentation J Bone Joint Surg Br, August 1, 2009; 91-B(8): 1078 - 1082. [Abstract] [Full Text] [PDF]

				J. Sigmond, R. J. Honeywell, T. J. Postma, C. M. F. Dirven, S. M. de Lange, K. van der Born, A. C. Laan, J. C. A. Baayen, C. J. Van Groeningen, A. M. Bergman, et al. Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer Ann. Onc., January 1, 2009; 20(1): 182 - 187. [Abstract] [Full Text] [PDF]

				S. A. Veltkamp, J. H. Beijnen, and J. H.M. Schellens Prolonged Versus Standard Gemcitabine Infusion: Translation of Molecular Pharmacology to New Treatment Strategy Oncologist, March 1, 2008; 13(3): 261 - 276. [Abstract] [Full Text] [PDF]

				T. Yeo, J Kintner, R Armand, R Perez, and L. Lewis Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells Human and Experimental Toxicology, December 1, 2007; 26(12): 911 - 921. [Abstract] [PDF]

				P. M. Specenier, D. Van den Weyngaert, C. Van Laer, J. Weyler, J. Van den Brande, M. T. Huizing, J. Dyck, D. Schrijvers, and J. B. Vermorken Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data Ann. Onc., November 1, 2007; 18(11): 1856 - 1860. [Abstract] [Full Text] [PDF]

				S. Michienzi, B. Bucci, C. Verga Falzacappa, V. Patriarca, A. Stigliano, L. Panacchia, E. Brunetti, V. Toscano, and S. Misiti 3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy J. Endocrinol., May 1, 2007; 193(2): 209 - 223. [Abstract] [Full Text] [PDF]

				D. E. Milenic, K. Garmestani, E. D. Brady, P. S. Albert, A. Abdulla, J. Flynn, and M. W. Brechbiel Potentiation of High-LET Radiation by Gemcitabine: Targeting HER2 with Trastuzumab to Treat Disseminated Peritoneal Disease Clin. Cancer Res., March 15, 2007; 13(6): 1926 - 1935. [Abstract] [Full Text] [PDF]